Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEN BETA is an investigational recombinant protein therapeutic being developed by Ventria Bioscience for the treatment of gastroenteritis. The product is manufactured using Ventria's proprietary ExpressTec platform, which utilizes genetically modified rice grains to express human proteins at a high scale and low cost. While specific details regarding the protein's identity are limited in public disclosures, VEN BETA is part of a therapeutic pipeline focused on infectious and inflammatory diseases of the gastrointestinal tract. It is likely a recombinant version of a human antimicrobial or immunomodulatory protein, such as a defensin, designed to enhance the gut's innate immune response and combat enteric pathogens. The candidate is currently in the early stages of development with a pending clinical phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VEN BETA.